WO1999013882A1 - Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin - Google Patents
Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin Download PDFInfo
- Publication number
- WO1999013882A1 WO1999013882A1 PCT/US1998/018850 US9818850W WO9913882A1 WO 1999013882 A1 WO1999013882 A1 WO 1999013882A1 US 9818850 W US9818850 W US 9818850W WO 9913882 A1 WO9913882 A1 WO 9913882A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- days
- combination
- levonorgestrel
- administered
- progestin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Definitions
- progestins include, but are not limited to levonorgestrel, norgestrel, desogestrel, 3-ketodesogestrel, norethindrone, gestodene, norethisterone acetate, norgestimate, osaterone, cyproterone acetate, trimegestone, dienogest, and drospirenone. It is more preferred that the progestin is levonorgestrel. When levonorgestrel is used as the progestin during the first 23-25 days of the cycle, it is preferred that the daily dosage of levonorgestrel is 30-150 ⁇ g, with 50-100 ⁇ g being more preferred, and 90 ⁇ g being most preferred.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU92286/98A AU759925B2 (en) | 1997-09-12 | 1998-09-09 | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
CA002301162A CA2301162A1 (en) | 1997-09-12 | 1998-09-09 | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
JP2000511503A JP2001516720A (en) | 1997-09-12 | 1998-09-09 | Oral contraceptive formulation having progestin / estrogen first phase and progestin second phase |
EP98944837A EP1011681A1 (en) | 1997-09-12 | 1998-09-09 | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92853097A | 1997-09-12 | 1997-09-12 | |
US08/928,530 | 1997-09-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999013882A1 true WO1999013882A1 (en) | 1999-03-25 |
Family
ID=25456367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/018850 WO1999013882A1 (en) | 1997-09-12 | 1998-09-09 | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1011681A1 (en) |
JP (1) | JP2001516720A (en) |
CN (1) | CN1270521A (en) |
AU (1) | AU759925B2 (en) |
CA (1) | CA2301162A1 (en) |
WO (1) | WO1999013882A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003041719A1 (en) * | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Method of contraception in mammalian females and pharmaceutical kit for use in such method |
JP2003518013A (en) * | 1999-10-25 | 2003-06-03 | ラボラトワール テラメックス | New contraceptives and their preparation |
WO2003077925A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Sulfatase inhibiting continuous progestogen contraceptive regimens |
WO2003077926A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
US7749987B2 (en) | 1996-10-08 | 2010-07-06 | Laboratorie Theramek | Contraception method |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL213122B1 (en) | 2001-12-05 | 2013-01-31 | Duramed Pharmaceuticals | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
AU2003222273A1 (en) * | 2002-03-11 | 2003-09-29 | Janssen Pharmaceutica N.V. | Sulfatase inhibiting progestogen-only contraceptive regimens |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
CN104546870B (en) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | A kind of contraceptive |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0368373A1 (en) * | 1988-10-13 | 1990-05-16 | Akzo Nobel N.V. | Multi-phase contraceptive preparation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19549264A1 (en) * | 1995-12-23 | 1997-06-26 | Schering Ag | Contraception procedure and kit |
-
1998
- 1998-09-09 EP EP98944837A patent/EP1011681A1/en not_active Withdrawn
- 1998-09-09 AU AU92286/98A patent/AU759925B2/en not_active Ceased
- 1998-09-09 CA CA002301162A patent/CA2301162A1/en not_active Abandoned
- 1998-09-09 CN CN98809067A patent/CN1270521A/en active Pending
- 1998-09-09 JP JP2000511503A patent/JP2001516720A/en active Pending
- 1998-09-09 WO PCT/US1998/018850 patent/WO1999013882A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0368373A1 (en) * | 1988-10-13 | 1990-05-16 | Akzo Nobel N.V. | Multi-phase contraceptive preparation |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7749987B2 (en) | 1996-10-08 | 2010-07-06 | Laboratorie Theramek | Contraception method |
JP2003518013A (en) * | 1999-10-25 | 2003-06-03 | ラボラトワール テラメックス | New contraceptives and their preparation |
EP2020236A1 (en) | 1999-10-25 | 2009-02-04 | Laboratoire Theramex | Contraceptive medicament based on a progestative and oestrogen, method for producing the same, and use |
WO2003041719A1 (en) * | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Method of contraception in mammalian females and pharmaceutical kit for use in such method |
WO2003077925A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Sulfatase inhibiting continuous progestogen contraceptive regimens |
WO2003077926A1 (en) * | 2002-03-11 | 2003-09-25 | Janssen Pharmaceutica N.V. | Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens |
Also Published As
Publication number | Publication date |
---|---|
CA2301162A1 (en) | 1999-03-25 |
AU759925B2 (en) | 2003-05-01 |
CN1270521A (en) | 2000-10-18 |
JP2001516720A (en) | 2001-10-02 |
AU9228698A (en) | 1999-04-05 |
EP1011681A1 (en) | 2000-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5858405A (en) | Oral contraceptive | |
US5888543A (en) | Oral contraceptives | |
US5747480A (en) | Oral contraceptive | |
EP0956024B1 (en) | Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen | |
US6479475B1 (en) | Oral contraceptive | |
WO1998004246A2 (en) | Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen | |
US6451778B1 (en) | Oral contraceptive | |
EP0917466B1 (en) | Oral contraceptive | |
EP0921804B1 (en) | Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen | |
AU759925B2 (en) | Oral contraceptive preparation having a first phase comprising progestin/estrogen and a second phase comprising progestin | |
WO1998004267A1 (en) | Progestin/estrogen oral contraceptive | |
WO1998004266A1 (en) | Oral contraceptive | |
WO1997041868A1 (en) | Oral contraceptive | |
WO1997041870A1 (en) | Oral contraceptive | |
WO1997041869A1 (en) | Oral contraceptive | |
WO1997041872A1 (en) | Oral contraceptive | |
WO1997041871A1 (en) | Oral contraceptive | |
MXPA99000801A (en) | Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen | |
MXPA99000883A (en) | Oral contraceptive |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98809067.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998944837 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 92286/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2301162 Country of ref document: CA Ref document number: 2301162 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 511503 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998944837 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 92286/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998944837 Country of ref document: EP |